Sickness, Healthspan, and Longevity

Why the body breaks down.

The foundation of this section, because everything that follows, cancer, metabolic disease, autoimmunity, the failing brain, is a particular way that one underlying thing goes wrong, and this page builds that one thing. It is also the page that takes on the longevity field directly: what actually extends a healthy life, what merely promises to, and how to tell the real science from the expensive theatre that has grown up around it.

Start by clearing two stories, because between them they account for most of how people think about disease, and both are wrong in ways that matter.

The first is that serious disease is bad luck, a random misfortune, or its modern scientific-sounding version, a poor genetic hand you were dealt and can do nothing about. This is comforting in a way, it removes responsibility, but it is mostly false: genetics loads the dice for most of the common chronic diseases, but lifestyle and environment do far more of the throwing than the fatalistic story admits, and the conditions that now kill most people in wealthy societies are substantially conditions of how we live. The second story is the opposite error, increasingly loud, that disease is therefore a kind of personal failing that the right diet, the right supplements, and enough willpower can prevent and even cure, so that anyone who gets sick simply did not optimise hard enough. This is crueller and also false, and at its worst it gets people to refuse effective treatment for the promise of a metabolic cure that does not exist. The truth sits between them and is more useful than either: you have far more influence over whether and when these diseases arrive than the bad-luck story allows, and far less than the optimise-everything story promises, and the influence you have is real, mechanistic, and worth understanding precisely.

To understand it, stop thinking of the body as a machine that runs until a part breaks, and start thinking of it as something stranger and more accurate: a structure that is continuously falling apart and continuously rebuilding itself, every day, for your entire life.

I. The Body as an Economy of Damage and Repair

Every structure in you is under constant assault. Your DNA takes tens of thousands of damaging hits per cell per day, from radiation, from chemistry, from the simple errors of copying. Your proteins misfold and clump. Your cell membranes oxidise. Your mitochondria, the structures that turn food and oxygen into usable energy, throw off reactive by-products that damage the very cells they power. This damage is not a malfunction; it is the unavoidable cost of being a living thing that runs on energy, the wear that comes with the work. If nothing opposed it, you would degrade in days.

What opposes it is an equally constant, equally relentless programme of maintenance and repair. DNA is proofread and mended. Misfolded proteins are refolded or destroyed and replaced. Damaged components are digested and recycled. Worn-out cells are cleared and renewed from stem-cell reserves. The immune system patrols for threats and for cells that have turned dangerous. All of this costs energy, a great deal of it, which is why so much of what you eat and breathe goes simply to staying the same, to running the repair crews that keep the structure standing against the constant tendency to fall down.

Health, in this picture, is not a state you have; it is a balance you are continuously winning: repair keeping pace with damage. And almost everything this section calls disease is what happens when that balance tips, when the rate of damage outruns the rate of repair, locally or system-wide, for long enough that the structure starts to fail. This is the single idea the whole section runs on, and it is worth holding precisely because it reframes every disease that follows. Cancer is a repair failure of a specific kind, the cell that should have been caught and removed instead surviving and multiplying. Metabolic disease is the system overwhelmed by more energy substrate than it can safely handle. Neurodegeneration is the repair-and-clearance machinery of the most energy-hungry tissue in the body falling behind. Autoimmunity is the immune arm of the maintenance system turning on the structure it is meant to protect. They are four ways the same economy fails.

And ageing is the slow, background version of all of them: the gradual, lifelong tilt of the balance, as the repair systems themselves wear down and the damage they leave uncleared accumulates, until the probability of one system or another failing badly enough to call a disease rises steeply. This is why age is the single largest risk factor for nearly every chronic disease, far larger than any individual gene or habit. Ageing is not separate from the diseases of this section; it is their shared soil, the rising tide of unrepaired damage out of which each of them grows. Which is why understanding ageing is the foundation for understanding all of them, and why slowing it is the most upstream intervention there is.

II. The Hallmarks of Ageing

For a long time ageing was treated as an irreducible mystery, just the wearing-out of things, nothing to explain or address. That has changed. Ageing biology has identified a specific, interconnected set of cellular and molecular processes that drive the wearing-out, the hallmarks of ageing, and they have become the common language of the field. The current account names twelve, and the point of listing them is not to memorise a catalogue but to see that they are the concrete forms the damage-outrunning-repair tilt actually takes, and that they are deeply interconnected, each feeding the others.

They group into three tiers. The primary hallmarks are the root damage: genomic instability (accumulating DNA damage), telomere attrition (the protective caps on chromosomes shortening until cells can no longer safely divide), epigenetic alterations (the controls that decide which genes are switched on drifting out of their youthful pattern), loss of proteostasis (the protein quality-control system failing, so misfolded proteins accumulate), and disabled macroautophagy (the cellular recycling system, which digests and reuses damaged components, breaking down). The antagonistic hallmarks are responses to that damage that help in the short term and harm when chronic: deregulated nutrient-sensing (the pathways that read how much food energy is available drifting toward a state that accelerates ageing), mitochondrial dysfunction (the energy-producing machinery becoming less efficient and more damaging), and cellular senescence (damaged cells, rather than dying, entering a zombie-like state where they stop dividing but linger and secrete inflammatory signals). And the integrative hallmarks are the system-wide consequences that produce the actual decline: stem-cell exhaustion (the reserves that renew tissues running down), altered intercellular communication (the signalling between cells degrading), chronic inflammation (a persistent, low-grade inflammatory state, sometimes called inflammaging, that both results from and accelerates the rest), and dysbiosis (the disruption of the microbial communities, especially in the gut, that the body depends on).

Two of these deserve singling out, because they are the threads that run through this entire section and connect it back to the rest of the manual. Mitochondrial dysfunction is the energetic spine made literal: as the mitochondria age and falter, the cell’s energy supply drops and its damaging by-products rise, which is the damage-outruns-repair tilt at the level of the single cell, and it shows up again in every disease chapter to come. And chronic inflammation, inflammaging, is the same low-grade, smouldering immune activation that the mental-health chapters identified under depression, here recognised as a general driver of ageing and of all four diseases at once. Energy and inflammation, the two threads from the depression chapter, turn out to be two of the central threads of physical decline as well, because they are not separate stories. They are the same story, told at the scale of the whole body over a whole life.

A discipline about the hallmarks, because the framework is powerful and can be oversold. To qualify as a hallmark, a process must meet three tests: it appears with age, accentuating it accelerates ageing, and, the demanding one, intervening on it slows, stops, or reverses ageing. That third criterion is the exciting one and also the least proven, established convincingly in laboratory animals and short-lived model organisms, far less so in humans, where the timescales are long and the experiments correspondingly hard. The hallmarks are the best map we have of the mechanisms of ageing, and they are a genuine scientific achievement, and they are not yet a proven set of buttons we can press to extend human life. Holding that distinction is the difference between understanding the science and being sold the supplement that claims to act on it. The map is real. Most of the routes on it have not yet been driven in humans.

III. Healthspan, Not Lifespan

This is the distinction that should reorganise the whole goal, because the thing most people think they want is not the thing worth wanting.

Lifespan is how long you live. Healthspan is how long you live well, the years before chronic disease and decline set in. The two have come badly apart. Modern medicine has become good at extending lifespan, at keeping people alive through and after the diseases that would once have killed them, but much of that added time is added at the end, in a state of accumulated illness, disability, and decline. We have, to a significant degree, extended the sick years rather than the well ones, lengthening the period of dying rather than the period of living. For many people the last decade or more of a long life is a slow accumulation of conditions, medications, and lost function.

The goal worth having is therefore not more years as such, but the compression of morbidity: pushing the onset of chronic disease and decline as late as possible, so that the well years extend and the sick years at the end shrink toward as brief a period as possible. The ideal is not to die at 110 having been ill since 75; it is to live well and fully until close to the end and then decline quickly, what is sometimes called squaring the curve. This matters because it changes what you are aiming at and what counts as success. The interventions that merely extend lifespan without extending healthspan are not obviously worth wanting. The ones that extend healthspan, that keep the body’s damage-repair balance winning for longer, are the prize, and, as it turns out, they are mostly the same interventions that prevent the four diseases of this section, because all of it is the one underlying economy. Aim at healthspan, and lifespan tends to follow; aim at lifespan alone, and you may simply buy more sick years.

IV. Measuring How Fast You Are Ageing

If ageing is the rising tide of damage, a natural question follows: can you measure how fast it is rising in a given person, faster or slower than their years would suggest? Until recently the answer was no, but one of the genuine advances of the field is the development of biological age measures that try to capture how aged a body actually is, as distinct from how many birthdays it has had.

The most developed of these are the epigenetic clocks. Recall that one of the hallmarks is epigenetic alteration, the drift of the chemical marks (particularly DNA methylation) that control which genes are switched on. It turns out that drift is regular enough to read as a clock: by measuring the methylation state at a few hundred specific sites in the genome, algorithms can estimate a person’s age with striking accuracy, and, more usefully, can detect when someone’s biological age is running ahead of or behind their chronological age. The successive generations of these clocks, trained not just to predict age but to predict disease and death, have become genuinely impressive: the best of them predict time-to-death, time-to-heart-disease, and time-to-cancer better than chronological age does, and they respond in the expected directions to the things we already believe age people, smoking, obesity, and chronic stress accelerate the clock; education, exercise, and good diet are associated with a slower one.

This is a real advance, and it is also the place where the longevity industry most outruns the science, so the calibration has to be exact. What the clocks have genuinely shown is that they are powerful predictors, correlated with mortality and disease, responsive to lifestyle, useful as a research tool and, increasingly, as a way to ask whether an intervention is doing anything. What they have not yet established is that they are causal targets you can treat to, that deliberately lowering your methylation age by some intervention will actually extend your life, rather than merely changing the number the clock reports. The clock might be reading the damage rather than driving it, in which case gaming the reading need not change the underlying reality. This distinction, between a measure that predicts an outcome and a lever that changes it, is exactly the one the longevity-testing industry blurs when it sells you a clock reading and a protocol to improve it. The clocks are a genuine scientific tool and an early one, and “lower your biological age with our programme” is a claim that runs well ahead of what they have shown. Worth tracking, especially over time and for the direction it moves; not yet worth treating as the verdict on whether you are winning.

The frontier beyond measurement is genuinely startling and genuinely early: the demonstration, in cells and in animals, that the epigenetic clock can be partially reset, that mature cells can be reprogrammed toward a younger state using a specific set of factors, ameliorating some hallmarks of ageing and, in some animal experiments, restoring lost function. This is real, it is one of the most exciting results in the field, and it is a long way from a safe human intervention, the same reprogramming that rejuvenates cells can, pushed too far, turn them cancerous, which is a reminder that ageing and cancer are linked problems and that resetting the one risks unleashing the other. The frontier is real. It is not a clinic you can visit, whatever the marketing of the more expensive clinics implies.

V. The Longevity Field

There has never been more interest in extending human life, or more money and noise around it, and the result is a field where genuine science, promising-but-unproven science, and outright theatre sit side by side and get sold as if they were the same thing. Sorting them is most of what a person actually needs, so here is the field in three honest tiers: what has real evidence, what is promising but unproven, and what is overreach. The sorting principle is simple and it is the one running through this whole section, judge each thing by the strength of the actual evidence for the outcome that matters, healthspan, not by how exciting the mechanism sounds or how confidently it is marketed.

What Works

The interventions with the strongest evidence for extending healthy life are, almost without exception, the ones nobody can sell you at a premium, which is a large part of why they get less attention than they deserve. They are the foundations, and in the longevity context they are not gentle wellness advice, they are the most powerful geroprotective tools known, with human outcome data the glamorous interventions can only dream of.

Exercise is the closest thing that exists to a longevity drug, and if it could be patented it would be the most valuable medicine ever made. Two measures in particular predict who lives long and well with a strength that rivals or exceeds any other modifiable factor. Cardiorespiratory fitness, your VO2 max, the capacity of your heart and lungs to deliver oxygen, is among the strongest predictors of all-cause mortality there is; the difference in death rate between the least fit and the most fit dwarfs the effect of most disease risk factors, and improving fitness measurably lowers risk. And muscle mass and strength, often measured crudely as grip strength, predict mortality and the ability to stay independent into old age, which is why preserving muscle through resistance training is one of the highest-leverage things a person can do for their later decades. These are not associations dressed up as advice; they are among the most robust findings in the whole of human health, and they act directly on the hallmarks, exercise improves mitochondrial function, lowers chronic inflammation, supports autophagy and proteostasis, and improves the very nutrient-sensing and metabolic regulation that the next chapter is about. The single most evidence-based longevity intervention is to build and keep cardiovascular fitness and muscle, for life.

Alongside it sit the rest of the foundations, each with real outcome data: not smoking (one of the largest single modifiable factors there is), sleep (the repair window for much of the damage this section describes), a whole-food dietary pattern that keeps the metabolic system unburdened (the subject of the next chapter), maintained social connection (which predicts mortality on the scale the mental-health section described), and the avoidance of the things that demonstrably accelerate the clock, chronic uncontrolled stress, excess alcohol, environmental pollutants. None of this is exciting and all of it is true, and together it accounts for the great majority of the healthspan a person can actually influence. The unglamorous foundations are Tier One because the evidence puts them there, not as a placeholder until the real interventions arrive.

There is also a dietary-and-fasting signal here worth stating with its real nuance. The nutrient-sensing pathways are genuine hallmarks of ageing, and in animals, caloric restriction reliably extends lifespan, which has made fasting and restriction central to longevity culture. The honest version: periodic fasting and not chronically over-eating plausibly act on real ageing pathways and have genuine metabolic benefits, and the dramatic lifespan-extension results are far cleaner in short-lived animals than in humans, where the evidence is for metabolic improvement more than for proven life extension, and where aggressive restriction carries real costs, including the loss of the very muscle Tier One says to protect. Eat in a way that keeps the metabolic system unburdened and does not chronically overfeed; be sceptical of the more extreme fasting protocols sold as proven longevity tools.

What’s Promising

Below the foundations sits a tier of genuinely serious pharmacological candidates, drugs and compounds with real mechanistic backing, real animal results, and real human trials underway, but without the human outcome evidence that would justify the confidence with which they are often sold. These are not grift, the science is real and some of these may well prove out, but the honest status of every one of them is “promising and unproven,” and anyone telling you otherwise is ahead of the data.

Rapamycin is the most scientifically interesting. It inhibits the mTOR nutrient-sensing pathway, one of the hallmark mechanisms, and it extends lifespan in every model organism tested, including mammals, more reliably than almost any other intervention. That animal evidence is genuinely impressive. The human evidence is genuinely thin: there are fewer than a dozen small trials in healthy adults, mostly measuring biomarkers rather than outcomes, and recent critical reviews conclude plainly that there is as yet no clear clinical evidence that low-dose rapamycin slows ageing or extends healthspan in humans. Trials are ongoing. The gap between the strength of the animal data and the thinness of the human data is exactly where the longevity clinics operate, prescribing off-label on the strength of the mouse studies. The mechanism is real and the human case is unproven, both at once.

Metformin, the widely used and very safe diabetes drug, acts on AMPK and mitochondrial efficiency and has shown intriguing signals, some observational data hinting that diabetics on metformin outlive non-diabetics, which would be remarkable if it held. Whether it extends healthspan in non-diabetics is precisely the question the large TAME trial was designed to answer, and that answer is years away. Until then it is, in the honest phrase, evidence-informed but not evidence-proven, which is why some longevity physicians offer it cautiously and none can honestly call it established.

The NAD+ precursors (nicotinamide riboside and NMN) are among the most heavily marketed longevity supplements. NAD+ is a genuinely central molecule in energy metabolism and DNA repair, and it declines with age, and supplementing the precursors does reliably raise NAD+ levels in humans, the supplements are bioavailable and do engage the biology. What has not been shown is the part that matters: that raising NAD+ this way improves any clinical outcome, frailty, cognition, physical performance, let alone lifespan. The trials show the molecule goes up; they have not shown that you are better off for it. This is the cleanest example in the tier of a real mechanism oversold, the supplement does something measurable and has not been shown to do anything that helps.

Senolytics, drugs that selectively kill the senescent “zombie” cells that accumulate with age and drive inflammaging, are mechanistically among the most exciting, because clearing senescent cells rejuvenates aged mice strikingly. In humans the work is early, small pilot studies (the dasatinib-and-quercetin combination, and fisetin) showing the approach is feasible and reasonably safe and can reduce senescence markers, without yet showing the clinical benefits the animal work promises. Genuinely promising, genuinely early.

A structural point that explains the whole tier and is worth seeing clearly: the reason the human evidence is so thin for interventions that have been studied for years is partly that the definitive trials are enormously expensive, slow, and, crucially, unfundable for the most interesting candidates, because rapamycin and metformin are generic, off-patent drugs that no company can profit from, so nobody will pay for the trial that would settle the question. The evidence gap is not only scientific; it is an artefact of how research is funded, which is itself the kind of incentive problem this manual keeps finding. It means these interventions may stay in limbo, plausibly useful and never definitively proven, for a long time, and a person deciding about them is deciding under genuine and possibly permanent uncertainty rather than waiting for an answer that is reliably coming.

Too Ambitious

And then there is the theatre, and it has to be named directly, because it wears the costume of the tiers above and sells the confidence they lack. The pattern is consistent: take a real Tier Two mechanism or a Tier One foundation, and sell it with a certainty the evidence does not support, usually attached to a product.

The supplement stacks are the commonest form, dozens of compounds, the NAD precursors, resveratrol, the rest, sold as a proven longevity regimen when the honest status of nearly every one is unproven and of many is “raises a number without known benefit.” The biological-age testing sold as a verdict is another, the clock reading offered as proof that the protocol is working, when, as established above, the clocks are predictors not yet validated as causal targets and gaming the reading need not change the underlying ageing. The total-optimisation spectacle is the most visible, the figure who spends millions and takes a hundred-odd daily interventions and broadcasts his falling biological-age numbers as demonstration, which is not a controlled experiment but a sample of one running every variable at once, from which nothing can be learned about what, if anything, works, however sincere the participant. And beneath all of it sits the reframing of ageing as a personal optimisation project at which one can win or fail, which quietly converts a universal biological process into a status competition and a market, and sells the anxiety along with the cure.

The thing to hold, and it is the balance this whole section runs on, is that calling out the theatre is not the same as dismissing the science, and the two are constantly confused in both directions. The grift is real and worth refusing. And the underlying science, the hallmarks, the foundations, the serious Tier Two candidates, is also real and worth taking seriously, and the reflex that dismisses all of longevity as snake oil because so much of its marketing is snake oil throws out a genuine and important field along with the hucksters. The discipline is to do neither, to refuse the overreach and respect the science, which means judging each specific claim by its specific evidence rather than by the company it keeps.

VI. Tying It Together

The body is a structure that survives by continuously repairing itself against constant damage, and health is that repair keeping pace. Ageing is the slow, lifelong tilt of the balance as the repair systems themselves wear down, captured in the dozen interconnected hallmarks whose two central threads, faltering cellular energy and rising chronic inflammation, run through every disease in this section and connect it to the dysregulation the mental-health chapters described. The four diseases that follow, cancer, metabolic disease, autoimmunity, and neurodegeneration, are four ways this one economy fails, which is why they share risk factors, share mechanisms, and share, to a striking degree, the same prevention.

The goal worth pursuing is not raw lifespan but healthspan, the compression of the sick years, and the means are clearer and less exotic than the longevity industry implies. The interventions with real evidence are the unglamorous foundations, cardiovascular fitness and muscle above all, then sleep, a metabolically unburdening diet, connection, and the avoidance of what accelerates the damage, and they account for most of the healthspan a person can actually influence. Above them sits a tier of serious, promising, genuinely unproven pharmacological candidates worth watching and worth scepticism in equal measure, and above that a layer of theatre that sells the confidence the evidence lacks. You can measure your ageing, roughly and informatively, with biological-age clocks, as long as you hold them as predictors rather than verdicts. And none of it, not the foundations and certainly not the frontier, is a substitute for treating disease that has already arrived, which is where the next chapters, and the floor that governs them, begin. The single most defensible longevity strategy is also the least sellable: build fitness and muscle, protect sleep and metabolic health, stay connected, avoid the accelerators, and treat the exotic interventions as experiments to watch rather than answers to buy.